Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AMED CoROCO:7575 56 EV-to-EBITDA is 7.60 as of Sep. 11, 2026, which is 39% below its 10-year median of 12.45. GuruFocus rates ROCO:7575 with a GF Score™ of 56/100 and a GF Value™ of NT$63.31 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 516 Medical Devices & Instruments companies, AMED Co ranks better than 75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, AMED Co's enterprise value is NT$815.7 Mil.
AMED Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$107.3 Mil. Therefore, AMED Co's EV-to-EBITDA for today is 7.60.
The historical rank and industry rank for AMED Co's EV-to-EBITDA or its related term are showing as below:
ROCO:7575'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.34 Med: 12.45 Max: 18.68
Current: 7.6
During the past 7 years, the highest EV-to-EBITDA of AMED Co was 18.68. The lowest was 7.34. And the median was 12.45.
ROCO:7575's EV-to-EBITDA is ranked better than 75% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.925
vs ROCO:7575: 7.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-09-11), AMED Co's stock price is NT$11.45.
AMED Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.190. Therefore, AMED Co's PE Ratio (TTM) for today is 9.62.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
AMED Co's share price for today is NT$11.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AMED Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$1.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for AMED Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7575 vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, AMED Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AMED Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AMED Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AMED Co's EV-to-EBITDA falls into.
AMED Co's current Enterprise Value is NT$815.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. AMED Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was NT$107.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AMED Co (ROCO:7575) has a EV-to-EBITDA of 7.60 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AMED Co. This is 39% below median its historical median of 12.45. Over the past decade, AMED Co's EV-to-EBITDA has ranged from 7.34 to 18.68. According to the industry distribution chart, AMED Co ranks #129 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 25%.
Is AMED Co's EV-to-EBITDA too high?
AMED Co's current EV-to-EBITDA of 7.60 is 39% below median its 10-year median of 12.45. Over the past 10 years, this metric has ranged from a low of 7.34 to a high of 18.68. The Medical Devices & Instruments industry median EV-to-EBITDA is 13.93. AMED Co's value of 7.60 is 45.4% below this industry median. Based on the distribution chart, AMED Co ranks #129 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, AMED Co has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AMED Co's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, AMED Co ranks #129 out of 516 companies for EV-to-EBITDA. This places AMED Co in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.93. AMED Co's value of 7.60 is 45.4% below this benchmark. Historically, AMED Co's own EV-to-EBITDA has ranged from 7.34 to 18.68 over the past decade. While the company's 10-year median is 12.45 vs. the industry median of 13.93, AMED Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.93, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AMED Co's current EV-to-EBITDA of 7.60 is 45.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on AMED Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AMED Co's current EV-to-EBITDA is 7.60, which is 39% below median its own 10-year median of 12.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AMED Co stock overvalued right now?
Based on GuruFocus' analysis, AMED Co (ROCO:7575) is currently considered Possible Value Trap. The stock's GF Value™ is NT$63.31, compared to a current price of NT$11.45 — trading 81.9% below its estimated fair value. The current EV-to-EBITDA is 7.60, which is 39% below median its 10-year median of 12.45 and 45.4% below the Medical Devices & Instruments industry median of 13.93. AMED Co's overall GF Score™ is 56/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For AMED Co (ROCO:7575), the current EV-to-EBITDA is 7.60 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AMED Co (ROCO:7575) Overvalued in 2026?
Based on GuruFocus' analysis, AMED Co stock appears to be undervalued.
The current stock price of NT$11.45 is trading 81.9% below its estimated GF Value™ of NT$63.31.
GuruFocus considers AMED Co to be Possible Value Trap.
Key valuation signals for ROCO:7575:
EV-to-EBITDA: 7.60 (39% below median its 10-year median of 12.45)
GF Value™: NT$63.31 vs. price of NT$11.45 (81.9% below fair value)
Industry Position: 45.4% below the Medical Devices & Instruments median (#129 of 516)
No single metric tells the full story. See the ROCO:7575 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AMED Co Ltd is fully committed to the research and development of UV photopolymerized hydrogels. It is a professional research and development and manufacturing company of wound dressing materials, providing proper wound care solutions, and marketing the product under the brand of Heli Dressing.
56GF Score
Get the complete analysis for ROCO:7575
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7575 has been successfully added to your 
